# Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

> **NCT06797622** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan (T-DXd)

## Key facts

- **NCT ID:** NCT06797622
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-04-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797622, "Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06797622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*